Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy

The success of immunotherapy relies on the participation of all arms of the immune system and the role of CD4+ T lymphocytes in preventing tumor growth is now well established. Understanding how tumors evade immune responses holds the key to the development of cancer immunotherapies. In this review,...

Descripción completa

Detalles Bibliográficos
Autores principales: Thibodeau, Jacques, Bourgeois-Daigneault, Marie-Claude, Lapointe, Réjean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489746/
https://www.ncbi.nlm.nih.gov/pubmed/23162758
http://dx.doi.org/10.4161/onci.21205
_version_ 1782248773616926720
author Thibodeau, Jacques
Bourgeois-Daigneault, Marie-Claude
Lapointe, Réjean
author_facet Thibodeau, Jacques
Bourgeois-Daigneault, Marie-Claude
Lapointe, Réjean
author_sort Thibodeau, Jacques
collection PubMed
description The success of immunotherapy relies on the participation of all arms of the immune system and the role of CD4+ T lymphocytes in preventing tumor growth is now well established. Understanding how tumors evade immune responses holds the key to the development of cancer immunotherapies. In this review, we discuss how MHC Class II expression varies in cancer cells and how this influences antitumor immune responses. We also discuss the means that are currently available for harnessing the MHC Class II antigen presentation pathway for the development of efficient vaccines to activate the immune system against cancer.
format Online
Article
Text
id pubmed-3489746
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-34897462012-11-16 Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy Thibodeau, Jacques Bourgeois-Daigneault, Marie-Claude Lapointe, Réjean Oncoimmunology Review The success of immunotherapy relies on the participation of all arms of the immune system and the role of CD4+ T lymphocytes in preventing tumor growth is now well established. Understanding how tumors evade immune responses holds the key to the development of cancer immunotherapies. In this review, we discuss how MHC Class II expression varies in cancer cells and how this influences antitumor immune responses. We also discuss the means that are currently available for harnessing the MHC Class II antigen presentation pathway for the development of efficient vaccines to activate the immune system against cancer. Landes Bioscience 2012-09-01 /pmc/articles/PMC3489746/ /pubmed/23162758 http://dx.doi.org/10.4161/onci.21205 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Review
Thibodeau, Jacques
Bourgeois-Daigneault, Marie-Claude
Lapointe, Réjean
Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy
title Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy
title_full Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy
title_fullStr Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy
title_full_unstemmed Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy
title_short Targeting the MHC Class II antigen presentation pathway in cancer immunotherapy
title_sort targeting the mhc class ii antigen presentation pathway in cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489746/
https://www.ncbi.nlm.nih.gov/pubmed/23162758
http://dx.doi.org/10.4161/onci.21205
work_keys_str_mv AT thibodeaujacques targetingthemhcclassiiantigenpresentationpathwayincancerimmunotherapy
AT bourgeoisdaigneaultmarieclaude targetingthemhcclassiiantigenpresentationpathwayincancerimmunotherapy
AT lapointerejean targetingthemhcclassiiantigenpresentationpathwayincancerimmunotherapy

Ejemplares similares